Company intelligence / Profile preview

Vicuron Pharmaceuticals

King Of Prussia, Pennsylvania, United Statessec.gov ↗

Ownership: Private
Development stage: Other

Overview

Vicuron had two late-stage anti-infective drugs under FDA review at the time of its acquisition. Anidulafungin showed superiority over fluconazole for invasive candidiasis in Phase III trials. Dalbavancin demonstrated efficacy against resistant Gram-positive pathogens with once-weekly dosing and positive results in complicated skin/soft tissue infection trials as well as catheter-related bloodstream infection studies.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Partnerships

Collaborations with major pharmaceutical companies for orally administered antibiotics and antifungals prior to acquisition

Beyond the preview

Go deeper on Vicuron Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vicuron Pharmaceuticals.

Explore the full profile